Foghorn therapeutics inc. (FHTX) 2025Q3 financial report shows revenue of 8.15M USD, with a YoY growth rate of 4.42%. This figure indicates that Foghorn therapeutics inc. (FHTX)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Foghorn therapeutics inc. (FHTX)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.